Published in Ann Intern Med on September 15, 1992
Compliance with public sector HIV medical care. J Natl Med Assoc (1995) 1.49
Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob Agents Chemother (1993) 1.06
Pre-exposure chemoprophylaxis for HIV: it is time. Retrovirology (2004) 0.96
Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro. Antimicrob Agents Chemother (1994) 0.93
Glucuronidation of 3'-azido-3'-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid. Antimicrob Agents Chemother (1998) 0.91
Swainsonine protects both murine and human haematopoietic systems from chemotherapeutic toxicity. Br J Cancer (1999) 0.85
Immunomodulatory effect of zidovudine (ZDV) on cytotoxic T lymphocytes previously exposed to ZDV. Antimicrob Agents Chemother (2002) 0.75
Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz. Pharmacol Res (2016) 0.75
Immunosuppressive effect of zidovudine. Ann Intern Med (1993) 0.75
Immunosuppressive effect of zidovudine. Ann Intern Med (1993) 0.75
Correlation between antiretroviral resistance mutations, biological parameters, and clinical evolution in zidovudine-treated patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis (1997) 0.75
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA (2000) 7.81
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA (1996) 5.29
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA (1998) 4.42
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med (1996) 4.03
Staphylococcus epidermidis infections. Ann Intern Med (1983) 3.57
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA (2001) 3.28
Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med (2001) 2.08
Methylation of the viral genome in an in vitro model of herpes simplex virus latency. Proc Natl Acad Sci U S A (1982) 1.56
Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr (2000) 1.45
Infiltration of the lower respiratory tract by helper/inducer T lymphocytes in HTLV-1-associated adult T-cell leukemia/lymphoma. Am J Med (1991) 1.43
A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia. Aust N Z J Med (2000) 1.42
Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS (2000) 1.42
HIV-1 Tat modulates invasion by a bacterial enteric pathogen into a human intestinal cell line. AIDS (1995) 1.39
In vitro modification of human immunodeficiency virus infection by granulocyte-macrophage colony-stimulating factor and gamma interferon. Proc Natl Acad Sci U S A (1986) 1.35
Cytomegalovirus vasculitis. Case reports and review of the literature. Medicine (Baltimore) (1994) 1.24
Host determinants in HIV infection and disease. Part 2: genetic factors and implications for antiretroviral therapeutics. Ann Intern Med (2001) 1.24
Treatment of Listeria monocytogenes infection with trimethoprim-sulfamethoxazole: case report and review of the literature. Rev Infect Dis (1986) 1.22
The herpes simplex virus immediate-early protein, ICP4, is required to potentiate replication of human immunodeficiency virus in CD4+ lymphocytes. J Virol (1989) 1.22
Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay. Antimicrob Agents Chemother (1992) 1.22
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis (1998) 1.20
The acute aseptic meningitis syndrome. Infect Dis Clin North Am (1990) 1.20
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. Ann Intern Med (2001) 1.18
Temporal cluster of herpes simplex encephalitis: investigation by restriction endonuclease cleavage of viral DNA. J Infect Dis (1980) 1.17
HIV fusion and its inhibition. Antiviral Res (2001) 1.13
Host determinants in HIV infection and disease. Part 1: cellular and humoral immune responses. Ann Intern Med (2001) 1.13
Activation of human immunodeficiency virus by herpes simplex virus. J Infect Dis (1992) 1.13
Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin Infect Dis (2001) 1.09
Epstein-Barr virus-induced infectious mononucleosis complicated by acute renal failure: case report and review. Clin Infect Dis (1996) 1.05
Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team. J Infect Dis (1998) 1.04
Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women. Osteoporos Int (2010) 1.03
Ganciclovir therapy of severe cytomegalovirus infections in solid-organ transplant recipients. Transplantation (1988) 1.01
Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 0.99
Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team. J Infect Dis (1998) 0.96
Kinetics of sealing for transient electropores in isolated mammalian skeletal muscle cells. Bioelectromagnetics (1999) 0.95
Herpes simplex virus infection of human T-cell subpopulations. Infect Immun (1982) 0.95
Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group. Antimicrob Agents Chemother (1994) 0.95
Physiological effects of HIV infection on human intestinal epithelial cells: an in vitro model for HIV enteropathy. AIDS (1994) 0.94
Inactivation of human immunodeficiency virus by Betadine products and chlorhexidine. J Acquir Immune Defic Syndr (1989) 0.94
Antiretroviral therapy: reverse transcriptase inhibition. Antimicrob Agents Chemother (1992) 0.92
Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. AIDS Res Hum Retroviruses (2000) 0.92
Effects of recombinant soluble CD4 (rCD4) on HIV-1 infection of monocyte/macrophages. J Infect Dis (1990) 0.90
Frequent identification of HIV-1 DNA in bronchoalveolar lavage cells obtained from individuals with the acquired immunodeficiency syndrome. Am Rev Respir Dis (1991) 0.90
Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation (1995) 0.90
Serologic diagnosis of focal pneumonia caused by Cryptococcus neoformans. Am Rev Respir Dis (1985) 0.88
Activation and suppression of herpes simplex virus in a human T lymphoid cell line. J Immunol (1981) 0.88
Antiretroviral resistance testing comes of age. Antivir Ther (2000) 0.88
Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy. J Infect Dis (2001) 0.87
Parasitic sinusitis and otitis in patients infected with human immunodeficiency virus: report of five cases and review. Clin Infect Dis (1997) 0.86
Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm. Nat Med (2003) 0.86
Disseminated cryptococcosis diagnosed on peripheral blood smear in a patient with acquired immunodeficiency syndrome. Am J Med (1990) 0.85
Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition. Antimicrob Agents Chemother (1992) 0.85
Viral aseptic meningitis in the United States: clinical features, viral etiologies, and differential diagnosis. Curr Clin Top Infect Dis (1992) 0.85
Neuromuscular function in HIV infection: analysis of a placebo-controlled combination antiretroviral trial. AIDS Clinical Group 175/801 Study Team. AIDS (1998) 0.84
Alpha interferon and acyclovir treatment of herpes simplex virus in lymphoid cell cultures. Antimicrob Agents Chemother (1982) 0.84
Transient and stable ionic permeabilization of isolated skeletal muscle cells after electrical shock. J Burn Care Rehabil (1993) 0.82
HTLV-III/LAV infection in kidney and liver transplantation. Transplant Proc (1987) 0.82
Effect of the calcium channel blocker verapamil on human immunodeficiency virus type 1 replication in lymphoid cells. J Infect Dis (1991) 0.81
Diarrheal disease in patients infected with human immunodeficiency virus in Bangkok, Thailand. Am J Trop Med Hyg (1999) 0.80
Pulmonary complications of orthotopic liver transplantation. Transplantation (1986) 0.80
The pathophysiology of enhanced susceptibility to murine cytomegalovirus respiratory infection during short-term exposure to 5 ppm nitrogen dioxide. Am Rev Respir Dis (1988) 0.79
Pathogenicity and diversity of HIV and implications for clinical management: a review. J Acquir Immune Defic Syndr (1994) 0.78
Virologic and regimen termination surrogate end points in AIDS clinical trials. JAMA (2001) 0.77
Ganciclovir hepatotoxicity. Pharmacotherapy (1987) 0.77
Herpes simplex virus replication in interleukin-2-stimulated human T cells. J Infect Dis (1985) 0.77
Effects of recombinant interleukin-2 on resting human T lymphocytes. J Biol Response Mod (1986) 0.77
Evaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. Participating Laboratories of The AIDS Clinical Trials Group. J Clin Microbiol (1996) 0.77
Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: combination therapy. Hosp Pract (Off Ed) (1992) 0.77
Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals. Antivir Ther (1997) 0.76
In vivo effects of interleukin 3 in HIV type 1-infected patients with cytopenia. AIDS Res Hum Retroviruses (1995) 0.75
Human T-lymphotropic virus type III infection in previously immunocompromised hosts. J Clin Oncol (1986) 0.75
Treatment of HIV infection: the antiretroviral nucleoside analogues. Introduction. Hosp Pract (Off Ed) (1992) 0.75
Infusion phlebitis associated with a programmable syringe-pump system versus gravity-feed minibottles. Clin Pharm (1987) 0.75
Acyclovir-associated fever: a case report. Pharmacotherapy (1987) 0.75
Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine. AIDS Res Hum Retroviruses (2000) 0.75
Isolation of human immunodeficiency virus and serum neutralising antibody. Lancet (1986) 0.75
Infectious complications with the use of cyclosporine versus azathioprine after cadaveric kidney transplantation. Am J Surg (1987) 0.75
An approach to antiretroviral treatment of HIV disease. Nucleoside monotherapy. Hosp Pract (1995) (1995) 0.75
Lack of in vivo effect of granulocyte-macrophage colony-stimulating factor on human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (1996) 0.75